Integer Holdings Corporation (ITGR) Stock

Integer Holdings Corporation (ITGR) is a Healthcare stock trading at $125.30 (as of 2026-08-20), with a market capitalization of $4.25B and a trailing P/E of 30.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Integer Holdings Corporation is a medical device outsource manufacturer with operations in the United States, Puerto Rico, Costa Rica, and internationally. It supplies medical device products across interventional cardiology, structural heart, vascular and neurovascular, and other procedure areas, as well as cardiac rhythm management, neuromodulation, batteries and device components, and related assemblies.

Understand Integer Holdings Corporation: how it makes money

Integer Holdings Corporation manufactures and sells medical devices as an outsource manufacturer, providing products across multiple interventional and procedural therapy areas.

Because Integer is a medical device outsource manufacturer, its profit model depends on converting incoming demand into production and sales, which is captured by Orders on Hand.

Business quality (Weak): Business scope is clear (medical device outsourcing across many procedure markets), and there are relevant operating indicators (Orders on Hand and category sales), but the provided data does not include a clean reportable segment revenue breakdown.

Valuation: At 23× earnings, ITGR trades 28% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Broad cardiology and vascular footprint: Cardio and Vascular Sales are a major portion of sales (58.0%), and the company also reports Cardiac Rhythm Management and Neuromodulation Sales (37.0%).
  • Demand visibility signal: Orders on Hand is reported at 0.73 USD_B, which can help indicate future production and sales opportunities.

Bear case

  • Backlog conversion risk: Even with Orders on Hand reported, revenue depends on converting orders into completed sales, which can be affected by execution and customer demand timing.
  • Concentration in specific therapy categories: With Cardio and Vascular representing 58.0% of sales, adverse shifts in those markets could have an outsized impact.
Valuation — source: SEC EDGAR (first-party)
Price$125.30
Market Cap$4.25B
P/E Ratio30.0
EV / EBITDA16.2
Price / Book2.51
Price / Sales2.29
FCF Yield2.3%
DCF Value (model)$19.64
DCF Upside vs Price-84.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.85B
Net Margin5.5%
Revenue Growth (YoY)0.5%
EPS Growth (YoY)-172.7%
FCF Growth (YoY)-87.8%
Financial Health — source: SEC EDGAR
Altman Z-Score2.91 (grey)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E30.0
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector38.9%
vs Industry-8.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($466.91M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOPayman Khales
Employees11,000
CountryUS
IPO Date2000-09-29

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Masimo Corporation (MASI)
  • Haemonetics Corporation (HAE)
  • iRhythm Technologies, Inc. (IRTC)
  • TransMedics Group, Inc. (TMDX)
  • AxoGen, Inc. (AXGN)
  • BioLife Solutions, Inc. (BLFS)
  • CONMED Corporation (CNMD)
  • CeriBell, Inc. (CBLL)
ITGR earnings history · ITGR institutional & insider holders · ITGR KPIs & operating metrics · ITGR financials · ITGR investor presentations & press releases · ITGR SEC filings · ITGR peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.